Our Accent is on the Data
We know everyone likes to think they're "different". Our accent is on the data. Does that make us different? You be the judge.
- The industry's thought and research leaders. (If you haven't yet, be sure to visit "Campaign Spy" and the "Winning Test".)
- Ongoing access to the benchmarks that your organization needs to know and strive for.
- A data-driven approach to transparent results reporting.
- A data-driven business-model that puts more net revenue in the hands of your organization.
Login or create an account to access the Campaign Spy
data.
ABOUT CAMPAIGN SPY
ABOUT THE WINNING TEST
Thumbs Up Thumbs Down!
ABOUT THUMBS UP THUMBS
DOWN
The Winning Test "Winner"
Dec 2/2011The Donnée Group is excited to announce that Kerry Whiteside of the Canadian Cancer Society is the winner of our Congress 2011 contest. Kerry's name was randomly drawn by our Director of Production, Wendy Tucker. Kerry wins a $50 gift card from Indigo. Congratulations Kerry!
The Winning Test Congress presentation slides
click here to download.
The Winning Test
Nov 28/2011
Would you like to learn what direct response tests are 'winning'
in the Canadian marketplace? Coming in early December, 'The Winning
Test'.
Campaign Spy
Nov 28/2011
Coming Soon! Imagine a single repository of the direct mail and
e-solicitations from across Canada! Watch for the launch of
Campaign Spy on December 15.
Thumbs Up/Thumbs Down
Nov 28/2011
How do donors to Canadian charities perceive your organization?
The most comprehensive market research survey of Canadian donors is
now underway. Contact us if you'd like to learn more about Thumbs
Up/Thumbs Down, or check back on January 15 when our survey will be
released.

It's Movember!!!
In the past, prostate cancer was not top of mind with the Canadian public. In many cases, people didn't know where the prostate was, its' function or the effects that the disease could have on men and their families. Things have changed a lot in the past few years. Prostate Cancer Canada and its blue tie have brought the disease to the forefront.











